-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Tag Archives: Incivek
Incivek telaprevir Drug Safety Communication
Translation Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek Combination Treatment): Drug Safety Communication – Serious Skin Reactions AUDIENCE: Internal Medicine, Gastroenterology, Dermatology ISSUE: FDA received reports of serious skin reactions, some fatal, in patients taking … Continue reading
Posted in Dermatology, FDA Label Change, FDA Safety Communication, Gastroenterology, Internal Medicine
Tagged Dermatology, Drug Safety Communication, Gastroenterology, Incivek, Incivek telaprevir Drug Safety Communication, Internal Medicine, Peginterferon Alfa, Ribavirin, Serious Skin Reactions, telaprevir
Comments Off
June 2012 Safety Labeling Changes
TranslationThe MedWatch June 2012 Safety Labeling Changes posting includes 35 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT. The “Summary Page” provides a listing of drug names and … Continue reading
Posted in FDA 2012, FDA Label Change, FDA Safety Communication
Tagged 1.5% ophthalmic, atomoxetine hydrochloride, Avodart, azithromycin, bepotastine besilate, Bepreve, bismuth subsalicylate, CellCept, darunavir, Drug Safety Communication, dutasteride, dutasteride and tamsulosin HCL, efavirenz, Estraderm, Estradiol, FDA notice, Helidac Therapy, Human 10%, Incivek, Jalyn, June 2012 Safety Labeling Changes, lisinopril, lisinopril/hydrochlorothiazide, Methergine, methylergonovine maleate, metronidazole and tetracycline hydrochloride, mycophenolate mofetil, mycophenolate mofetil hydrochloride, mycophenolic acid, Myfortic, Noxafil, posaconazole, Prezista, Prinivil, Prinzide, Privigen Immune Globulin Intravenous, Safety Communication, safety label changes, solifenacin succinate, Stelara, Strattera, Sustiva, tablets, telaprevir, transdermal, ustekinumab, Vesicare, Zithromax
Comments Off